Beckman Research Institute

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Retrieved on: 
Monday, April 1, 2024
Health, Stem Cells, Genetics, General Health, Research, Science, Biotechnology, Stem cell, B cell, Regenerative medicine, Agriculture, Global health, Lineage, Madrona Venture Group, Duke University, Beckman Research Institute, City, Columbia University, University, NanoString Technologies, Fierce, Doctor of Philosophy, Investment, Therapy, Microbiology, Partner, Corporate development, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
  • Most recently, Dr. Hubbert served in the leadership team at NanoString Technologies .
  • “We are excited to add such a talented executive to our management team in the newly created position of VP Corporate Development.
  • Dr. Hubbert’s decades of experience in cell therapy, strategic investment, and partnering make her a valuable and welcome addition to the Lineage team,” stated Brian M. Culley, CEO.

City of Hope to Present New Research at the American Association of Cancer Research (AACR) Annual Meeting 2024, Highlighting Promising Data on Prostate, Colorectal and Pancreatic Cancer

Retrieved on: 
Tuesday, March 12, 2024
Research, Other Health, General Health, Pharmaceutical, Oncology, Biometrics, Hospitals, Genetics, Health Technology, Science, Biotechnology, Health, Other Science, Breast cancer, Syngenic, Convergent, Computational biology, Patient, Distinguishing, Beckman Research Institute, City, Tumor microenvironment, PSCA, Haematopoietic system, Memory, AACR, Lymphocyte, Treatment, Convergent Science, Neoplasm, Road, Systems biology, CRC, Division, Microbiome, Hematology, Pharmaceutical industry

To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.

Key Points: 
  • To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.
  • They found that the model was sensitive to microbiome modulation and that the use of patient-derived human fecal matter transfers can significantly impact PSCA-CAR T cell directed anti-tumor responses.
  • , will also chair the inaugural AACR event called From Cancer Discoveries to Patients on April 4 and 5.
  • The event brings together leaders in clinical research, biotech and the investment community as part of AACR’s commitment to expediting the advancement of lifesaving cancer discoveries.

City of Hope Predicts 8 Important Cancer Trends in 2024

Retrieved on: 
Wednesday, January 17, 2024
Oncology, Health, Managed Care, General Health, Research, Science, Woman, Volunteering, Beckman Research Institute, Biology, Incidence, Prostate cancer, City, Translational Genomics Research Institute, Standard of care, Cancer, Risk, Artificial intelligence, National Cancer Institute, Acceleration, Diagnosis, Medicine, Diabetes, Deana, Stomach cancer, Geography, Irell & Manella, DNA, Policy, Bacteria, Drug development, Virus, Bone marrow, Transport, Organization, Colorectal cancer, Education, Fungus, Physician, Blood, Medicare, Hematology, Immunotherapy, Quality of life, Genetic testing, Millennials, Cell, Mortality, Patient, Federal Medical Centres, Whole genome sequencing, Lung cancer, Triple-negative breast cancer, Immune system

City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.

Key Points: 
  • City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.
  • “City of Hope will soon launch a comprehensive research study validating a blood test developed by researchers at City of Hope and TGen to detect cancers early.
  • Early detection is the key to curing cancer for many,” said Annette Walker, president of City of Hope Orange County.
  • “This is a primary reason City of Hope expanded its National Cancer Institute-designated expertise to Chicago, Phoenix and Atlanta.

EQS-News: Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER

Retrieved on: 
Thursday, October 26, 2023
FDA, IND, City of Hope, Nivolumab, Chitosan, Beckman Research Institute, Injection, News, Defense, CDMO, Nanoparticle, BMS, City, Lymphoma, Antibody, City of Hope National Medical Center, Animal, Molecular medicine, Melanoma, Cancer, Lung cancer, Therapy, Relatlimab, Endoplasmic reticulum, Breast, Patient, Peptide, DNA, Pharmaceutical industry, Vaccine

Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.

Key Points: 
  • Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.
  • The AccuTOXTM molecule can eradicate cancer cells via different mechanisms including the initiation of immunogenic cells death, endoplasmic reticulum stress and by causing direct damages to DNA.
  • AccuTOXTM triggers cancer tumor regression, Defence also recently demonstrated that encapsulated AccuTOXTM with chitosan nanoparticles triggers complete tumor regression in animals with pre-established solid lymphoma.
  • Further development and expanding applications on Defence’s leading AccuTOXTM therapeutic is ongoing and further news to be released upon results.

John D. Carpten, Ph.D., City of Hope’s Chief Scientific Officer, Elected to Prestigious National Academy of Medicine

Retrieved on: 
Monday, October 9, 2023
Science, DEI (Diversity, Equity and Inclusion), Biotechnology, Research, Oncology, Health, Professional Services, Genetics, Morgan, Incidence, National Academy of Medicine, Multimedia, Beckman Research Institute, Medicine, City of Hope National Medical Center, Irell & Manella, Biology, Breast cancer, NAM, Multiple myeloma, Mortality, Irell & Manella Graduate School of Biological Sciences, Cancer, National academy, Diabetes, Patient, City, Workforce, City of Hope, Policy, Colorectal cancer, Cell biology, African Americans, Health equity, Prostate cancer, Genomics, Deana, National Cancer Institute, Dietary supplement, Vaccine, Management, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20231009647781/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231009647781/en/
    John D. Carpten, Ph.D., chief scientific officer at City of Hope, was presented with one of the highest honors in health and medicine on Oct. 9, 2023, when he was elected to the National Academy of Medicine.
  • Carpten has numerous national leadership roles and is the first African American to chair the National Cancer Institute’s National Cancer Advisory Committee.
  • Carpten is director of the National Cancer Institute-designated City of Hope comprehensive cancer center and director of Beckman Research Institute of City of Hope.
  • “I am deeply humbled to be elected a member of the National Academy of Medicine.

EQS-News: DEFENCE’S BROAD AND VERSATILE ACCUM® TECHNOLOGY PLATFORM FOCUS ON CANCER THERAPEUTICS

Retrieved on: 
Saturday, September 16, 2023
Vaccine, Survival rate, City of Hope National Medical Center, DNA, Partnership, Therapy, Immunogenic cell death, Biotechnology, ARM, Cancer, Head, USD, Neck, Messenger, City, DNA repair, Cervical cancer, Melanoma, Immune system, HPV, Observation, ADC, Spacecraft, Beckman Research Institute, IND, Breast cancer, Pharmaceutical industry, Defense

The treatment regimens used with these ADCs usually require large doses, while the therapeutic response is limited or weak.

Key Points: 
  • The treatment regimens used with these ADCs usually require large doses, while the therapeutic response is limited or weak.
  • By bio-conjugating ADCs with Accum®, Defence has demonstrated improved potency of commercially available ADCs by 20 to 100 folds.
  • Its pipeline is well positioned to prevent cancer and/or enhance the efficacy of any bio-drug designed to target cancer.
  • Defence is focussing and dedicating its leadership against one of the biggest enemies of humanity: cancer.

City of Hope receives $32.3 million from the California Institute for Regenerative Medicine to advance innovative therapies for patients

Retrieved on: 
Wednesday, August 9, 2023
City of Hope, Diabetes, Bone marrow, California Institute for Regenerative Medicine, University of California, San Diego Performance-Based Skills Assessment, Patient, Division, CIRM, Canadian Aviation Regulations, Sickle cell disease, University, Gene, Endocrine & Metabolism Research Institute, Aplastic anemia, Research, Transplant, Immunology, Luca Zaia, Distinguishing, Safety, Cytomegalovirus, HLA, Cancer, Morgan, UCSD, Cell, Acute myeloid leukemia, CAR, CD33, Immune system, Food and Drug Administration, Mortality, LOS, B cell, Radiation, HIV, Clinical trial, Person, Irell & Manella Graduate School of Biological Sciences, Regenerative medicine, AML, City, Beckman Research Institute, Aaron, Haematopoietic system, Food, Vaccine, Pharmaceutical industry, Dentistry, Hope, Leukemia, Hematology

LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, were awarded $32.3 million from the California Institute for Regenerative Medicine (CIRM) to support three novel Phase 1 clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia and severe aplastic anemia. 

Key Points: 
  • Beckman Research Institute of City of Hope was awarded two-thirds of the $50 million in this latest round of CIRM awards, the highest of any entity in the state.
  • City of Hope is a leader in gene therapies, including bone marrow and blood stem cells transplants.
  • "We are hopeful that this will provide another treatment option for patients with this devastating disease and thankful for CIRM's funding."
  • City of Hope has treated patients with sickle cell diseases using this novel therapy in a clinical trial also funded by CIRM.

City of Hope scientists develop targeted chemotherapy able to kill all solid tumors in preclinical research

Retrieved on: 
Tuesday, August 1, 2023
Linda, Molecule, Alex's Lemonade Stand Foundation, DNA, Rituximab, Insulin, Human, City of Hope National Medical Center, City of Hope, R01, Neoplasm, Biotechnology, Cell Chemical Biology, Trastuzumab, Clinical trial, Ovary, Breast, Toxicity, Brain, Research, Gene expression, Prostate, Treatment of lung cancer, Cell, Molecular diagnostics, Translational Genomics Research Institute, Cetuximab, Experiment, RLL, Bangladesh Technical Education Board, DNA replication, National Cancer Institute, S phase, Australian Melanoma Research Foundation, Patient, Department of Defense Serum Repository, Apoptosis, LOS, Beckman Research Institute, Proliferating cell nuclear antigen, Therapy, Skin, PCNA, Vaccine, Pharmaceutical industry, Molecular oncology, City, Hope

LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research. As the scientists continue to investigate the foundational mechanisms that make this cancer-stopping pill work in animal models, they note that there is an ongoing Phase 1 clinical trial testing the City of Hope-developed therapeutic in humans.

Key Points: 
  • Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells.
  • The investigational chemotherapeutic is currently in a Phase 1 clinical trial in humans at City of Hope."
  • Now that we know the problem area and can inhibit it, we will dig deeper to understand the process to develop more personalized, targeted cancer medicines."
  • "City of Hope has world leaders in cancer research.

City of Hope appoints David W. Craig, Ph.D., as founding chair of its new Department of Integrative Translational Sciences within its Beckman Research Institute

Retrieved on: 
Thursday, June 29, 2023
City of Hope National Medical Center, Translational Genomics Research Institute, City of Hope, University, Keck School of Medicine of USC, Neurogenomics, Diabetes, Genomics, Biotechnology, National Cancer Institute, Research, USC, College of Engineering (KNUST), Science, City, Publication, Patient, Sequence, University of Washington School of Medicine, Medicine, Faculty, Reference genome, Beckman Research Institute, Health, Deana, Data science, Pharmaceutical industry, Management, Antibiotics, Hope

LOS ANGELES, June 29, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, today announced that effective June 30, David W. Craig, Ph.D., will be professor and founding chair of its newly created Department of Integrative Translational Sciences within Beckman Research Institute of City of Hope. Craig also will serve as deputy director of translational sciences at Beckman Research Institute and associate director of data science for City of Hope's National Cancer Institute-designated comprehensive cancer center in Los Angeles, which is the basic and clinical research innovation hub for its national cancer system.

Key Points: 
  • "We are excited to welcome Dr. Craig to City of Hope and look forward to his leadership in translational research that will contribute to innovative, personalized treatment for City of Hope patients throughout the United States."
  • The new Department of Integrative Translational Sciences will focus on precision measurement, data science and diversity.
  • It will seek to further improve both translational outcomes as well as the science underpinning the use of precision medicine.
  • Craig joins City of Hope from the University of Southern California, where he was co-director of the Institute of Translational Genomics and vice chair of the Department of Translational Genomics at Keck School of Medicine of USC.